Nestlé has issued a recall for certain batches of baby formula, mainly in Europe, due to potential contamination with a toxin that can lead to symptoms like nausea and vomiting. However, there are no affected products in Canada, as confirmed by the company.
The decision to recall products such as SMA, BEBA, and NAN infant formulas was made voluntarily by Nestlé as a precautionary step after concerns arose about the presence of cereulide, a toxin associated with food poisoning caused by specific bacteria strains. The Food Safety Authority of Ireland highlighted the potential dangers of this chemical, noting its heat resistance and ability to cause severe vomiting and nausea.
Nestlé emphasized its commitment to the safety of infants and initiated the recall as a proactive measure in adherence to their stringent quality and safety standards. The company conducted testing on their products following a quality issue with an ingredient from a supplier, and after completing the necessary tests, they are working with alternate suppliers to maintain formula supply.
Although the recall affects several countries, including Turkey, Argentina, the U.K., Ireland, and other European nations, Nestlé confirmed that Canada is not impacted. The Canadian Food Inspection Agency (CFIA) also verified the absence of the affected formulas in the Canadian market.
In case of any updates or if affected products are found in Canada, the CFIA assured the public of timely notifications through their recalls and safety alerts website. Nestlé has provided a list of batch numbers online for consumers to check and is advising those who purchased the affected formulas not to use them and to contact the company for a refund.
Austria’s health ministry reported that the recall affected over 800 products from more than 10 Nestlé factories, marking it as the largest recall in the company’s history, although these figures remain unconfirmed by Nestlé. The Swiss multinational company, a significant player in the global infant nutrition market, has experienced a decline in shares amidst this recall.
Infant formula contributes to Nestlé’s Nutrition and Health Science division, which played a substantial role in the company’s 2024 sales. The recall, which began on a smaller scale in December, adds to the challenges faced by Philipp Navratil, Nestlé’s new CEO, who aims to drive growth through a strategic portfolio review following recent management changes.